Prostate Cancer Preliminary Data From a Prospective, Multi-Centered Proof of Concept Study of 84 Men Into the Utility of Volition’s Nu.Q™ Assays to Diagnose Men with High-Grade Prostate Cancer Announced Today by VolitionRx Limited
VolitionRx Limited (NYSE AMERICAN: VNRX) has announced preliminary data from a prospective, multi-centered Proof of Concept Study of 84 men into the utility of Volition’s Nu.Q™ assays to diagnose men with high-grade prostate cancer.
At 88% specificity, the Volition panel of five assays (including PSA) identified 94% of high-grade prostate cancers that require treatment (as defined by Gleason Score1). This compares with just 33% identified by Prostate-Specific Antigen (PSA) alone.
“This is a very exciting outcome for us as we continue the development of our assays beyond colorectal cancer. The preliminary data from this study showed that Volition’s panel of assays identified men with potentially lethal high-grade prostate cancer with much greater accuracy than PSA alone. Based on this data, we believe that this test could assist clinicians in more accurate patient selection for prostate biopsy and treatment and substantially reduce the amount of unnecessary procedures in men with low-grade tumors or no tumor. The next step is to confirm these statistically significant findings in independent larger clinical trials” said Dr. Jake Micallef, Chief Scientific Officer at Volition.
Prostate cancer (PCA) is the second leading cause of cancer death in men in the U.S. after lung cancer2. Currently, PCA is diagnosed through medical history, physical examination and by elevated levels of PSA in the blood. Men suspected of PCA are given a prostate biopsy to confirm the presence of cancer. However, most men with elevated PSA levels referred for prostate biopsy either have no cancer or have low-grade cancer which needs monitoring but not treatment.